- Home
- HSIC vs LEGN Comparison
HSIC vs LEGN Comparison
Compare HSIC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSIC | LEGN |
|---|---|---|
| Founded | 1932 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 5.9B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HSIC | LEGN |
|---|---|---|
| Price | $76.74 | $21.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | ★ $76.50 | $69.67 |
| AVG Volume (30 Days) | 1.2M | ★ 2.7M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.70 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $12,938,000,000.00 | $909,045,000.00 |
| Revenue This Year | $5.35 | $68.83 |
| Revenue Next Year | $3.34 | $51.27 |
| P/E Ratio | $24.32 | ★ N/A |
| Revenue Growth | 3.51 | ★ 74.75 |
| 52 Week Low | $60.56 | $21.51 |
| 52 Week High | $82.49 | $45.30 |
Technical Indicators
Market Signals| Indicator | HSIC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.11 | 20.03 |
| Support Level | $76.34 | $26.43 |
| Resistance Level | $77.74 | $28.97 |
| Average True Range (ATR) | 1.44 | 1.25 |
| MACD | 0.11 | -0.41 |
| Stochastic Oscillator | 84.54 | 0.73 |
Price Performance
Historical ComparisonAbout HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.